Celyad Oncology SA (EBR:CYAD)

Market Cap	10.74M -36.8%
Revenue (ttm)	21.00K -88.7%
Net Income	830.00K
EPS	0.02
Shares Out	44.76M
PE Ratio	13.33
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	721
Open	0.2480
Previous Close	0.2400
Day's Range	0.2340 - 0.2480
52-Week Range	0.1600 - 0.6500
Beta	1.20
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 23, 2026

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: Euronext Brussels
• Ticker Symbol: CYAD

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 1, 2026

Data Sources Report a data error